Wuhan Keqian Biology Co Ltd
SSE:688526
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Wuhan Keqian Biology Co Ltd
Pre-Tax Income
Wuhan Keqian Biology Co Ltd
Pre-Tax Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Wuhan Keqian Biology Co Ltd
SSE:688526
|
Pre-Tax Income
¥438.1m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Pre-Tax Income
¥6.6B
|
CAGR 3-Years
30%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Pre-Tax Income
¥9.2B
|
CAGR 3-Years
33%
|
CAGR 5-Years
5%
|
CAGR 10-Years
13%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Pre-Tax Income
¥6.1B
|
CAGR 3-Years
15%
|
CAGR 5-Years
0%
|
CAGR 10-Years
6%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Pre-Tax Income
¥7.8B
|
CAGR 3-Years
23%
|
CAGR 5-Years
14%
|
CAGR 10-Years
32%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Pre-Tax Income
-¥721.4m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Wuhan Keqian Biology Co Ltd
Glance View
Wuhan Keqian Biology Co., Ltd. engages in the research, development, production, and sale of veterinary biological products. The company is headquartered in Wuhan, Hubei and currently employs 848 full-time employees. The company went IPO on 2020-09-22. The firm's main products are vaccines for swine and poultry. The firm mainly conducts its businesses within the China market.
See Also
What is Wuhan Keqian Biology Co Ltd's Pre-Tax Income?
Pre-Tax Income
438.1m
CNY
Based on the financial report for Dec 31, 2024, Wuhan Keqian Biology Co Ltd's Pre-Tax Income amounts to 438.1m CNY.
What is Wuhan Keqian Biology Co Ltd's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
10%
Over the last year, the Pre-Tax Income growth was -4%. The average annual Pre-Tax Income growth rates for Wuhan Keqian Biology Co Ltd have been -13% over the past three years , 10% over the past five years .
